See the DrugPatentWatch profile for ruxolitinib

Ruxolitinib is a drug manufactured by Apotex that is used to treat certain diseases. According to the Apotex website, ruxolitinib is a Janus kinase (JAK) inhibitor, which works by blocking the action of certain enzymes in the body that affect immune system function and inflammation [1].

More specifically, ruxolitinib is approved by the US Food and Drug Administration (FDA) for the treatment of certain blood disorders, including myelofibrosis and polycythemia vera [1]. Myelofibrosis is a type of bone marrow cancer that disrupts the body's normal production of blood cells, leading to anemia, fatigue, and an enlarged spleen [2]. Polycythemia vera is a type of blood cancer that causes the body to produce too many red blood cells, leading to symptoms such as fatigue, headaches, and a feeling of fullness in the left side of the abdomen [3].

It's important to note that ruxolitinib is not approved for the treatment of all types of blood disorders or other diseases. Patients should consult with their healthcare provider to determine if ruxolitinib is appropriate for their specific condition.

Sources:

* [1] Apotex. (n.d.). Ruxolitinib. Retrieved from <https://www.apotex.com/product-details/ruxolitinib>
* [2] Mayo Clinic. (2021, January 15). Myelofibrosis. Retrieved from <https://www.mayoclinic.org/diseases-conditions/myelofibrosis/symptoms-causes/syc-20369333>
* [3] American Society of Hematology. (n.d.). Polycythemia Vera. Retrieved from <https://www.hematology.org/conditions/polycythemia-vera>